Welcome to Africanews

Please select your experience

Watch Live


AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

Today marks an important step in turning the corner on the pandemic and getting things back to normal. Following the positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil, which showed the vaccine was highly effective in preventing COVID-19, we are confident that our united response, across the scientific community, industry, organisations, and governments, will make significant inroads in curbing the COVID-19 pandemic that has continued to claim thousands of lives every day in Africa and across the globe. We will continue to work hard to honour our commitment to make the vaccine available in a fair and equitable manner as rapidly as possible, following robust regulatory approval and meeting stringent efficacy and safety standards. It is a great day for innovation and for inclusion, an exciting moment for human health.

Barbara Nel Country President African Cluster: South Africa, Sub Saharan Africa, French Speaking Africa

Full AstraZeneca Regulatory News Service News Release available here (https://bit.ly/339VrKS).

Distributed by APO Group on behalf of AstraZeneca.

About AstraZeneca:
AstraZeneca (www.AstraZeneca.com) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.AstraZeneca.com and follow the Company on LinkedIn @AstraZeneca.

Media files
Download logo

Adenovirus vector
Africanews provides content from APO Group as a service to its readers, but does not edit the articles it publishes.